



About Bio-Pearl River Forum

As the richest province in China, Guangdong contributes approximately 12.5% of Chinese economic output. With its easy access to the ocean, proximity to Hong Kong, and historical links to overseas Chinese talents, Guangdong has played an integral role in China's economic development. Known as the "prosperous land of Medicine" in China and Southeast Asia, Guangdong also holds a leading position in the Chinese pharmaceutical industry.

In the era of globalization, as the Chinese pharmaceutical industry continues to play an increasingly important role in the global pharmaceutical industry, pharmaceutical research and development in Guangdong, however, faces great challenges, including stronger domestic and international competition and stricter regulations. The traditional characteristics of the pharmaceutical companies in Guangdong, including modest size, outdated organizational structure and management style, weakness in innovation, and lack of effective interaction and collaboration with the global biopharmaceutical industry, hinder further advancement of Guangdong's pharmaceutical development. The current global economic downturn has also considerably affected many factories in Guangdong. To survive and thrive in current global economy, Guangdong provincial government is determined to promote a technology and innovation-driven business model.

Headquartered in the U.S., the Chinese Biopharmaceutical Association (CBA) possesses a strong connection and interaction with both Chinese and U.S. biopharmaceutical industry. Since its inception, CBA has been playing a dynamic role in bridging the Chinese biopharmaceutical industry and the global, especially the U.S., biopharmaceutical industry. Members of CBA have expertise in every sector of biopharmaceutical research, development, and commercialization. By cohosting this international conference, entitled Bio-Pearl River Forum, with CBA, Guangdong provincial government intends to bring world-renowned experts to Guangdong to provide constructive suggestions and comments in terms of advancing the biotechnology and pharmaceutical development in Guangdong and the Pearl River delta.

The first Bio-Pearl River Forum is designed to create a platform for communication and collaboration among pharmaceutical companies, biotechnology companies, contract research organizations, research institutions, government agencies, as well as individual research scientists, entrepreneurs, and venture capitalists from China and other countries. The goals of the forum are to enhance interactions and collaborations among pharmaceutical companies in Guangdong, foreign companies, as well as domestic companies in other provinces; to improve interactions between the pharmaceutical industry and regulatory agencies, including China's State Food and Drug Administration (SFDA), the US Food and Drug Administration (FDA), and the European Medicines Agency (EMA); to help pharmaceutical and biotechnology companies in Guangdong, as well as companies in other provinces in China, improve regulatory compliance, particularly cGMP compliance; and to attract high-end overseas talents to Guangdong. It is believed that the Bio-Pearl River Forum will play an important role in the biotechnology and pharmaceutical innovation and commercialization not only in Guangdong and the Pearl River delta but also in other parts of China, as well as the world.